A Phase 2 interventional study of LCI699-matching placebo and LCI699 in Hypertension, sponsored by Novartis. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-02.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.
Among the 227 studies in Hypertension by Novartis, this one is the 183rd largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2009, is one of 29 in phase 2, and was the 155th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
By country, each count listing its studies:
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 17 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 309 across the 222 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
3 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 227 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
Drug: LCI699
Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Drug: LCI699
Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
Drug: LCI699
Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Drug: LCI699
Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
Drug: LCI699-matching placebo
LCI699-matching placebo oral capsules
LCI699 oral capsules
Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants
As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results \<400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.
Time frame: Up to Week 6
LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants
Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than \>500 nmol at 60 minutes after ACTH administration was expected.
Time frame: Up to Week 6
LCI699 Plasma Concentration Post LCI699 Administration at Day 7
Time frame: Predose and 3 hours post-dose on Day 7
Maximum Plasma Concentration (Cmax) of LCI699
Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Time of Maximum Plasma Concentration (Tmax) of LCI699
Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)
Time frame: Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699
Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Apparent Terminal Half-life (T1/2) of LCI699
Time frame: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Number of Participants With Adverse Event (AEs)
An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.
Time frame: Up to 8 weeks
Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.
Time frame: Week 6
Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.
Time frame: Week 6
Participants were enrolled at 10 investigative sites in the United States and Iceland from 14 January 2009 to 12 August 2009.
| Milestone | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo |
|---|---|---|---|---|---|
| Started | 12 | 12 | 13 | 13 | 13 |
| Completed | 10 | 9 | 9 | 1 | 11 |
| Not completed | 2 | 3 | 4 | 12 | 2 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Low adrenocorticotropic hormone (acth)- stimulated cortisol | 0 | 1 | 2 | 4 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Dose arm exceeds maximum tolerated dose (mtd) | 0 | 0 | 0 | 7 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results \<400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.
| milligrams (mg) | LCI699 |
|---|---|
| Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants | 1.30 (0.88 to 1.81) |
Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than \>500 nmol at 60 minutes after ACTH administration was expected.
| nanomoles per liter (nmol/L) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD | Placebo |
|---|---|---|---|---|---|
| Day 7 | 690.0 ± 32.288 | 669.40 ± 30.903 | 625.06 ± 30.965 | 562.04 ± 30.325 | 799.06 ± 31.161 |
| Day 28 | 634.87 ± 32.181 | 573.41 ± 30.642 | 554.79 ± 29.466 | 539.09 ± 32.826 | 804.86 ± 29.786 |
| Day 42 | 647.51 ± 45.593 | 626.08 ± 45.441 | 539.68 ± 37.146 | 479.91 ± 48.865 | 812.91 ± 39.096 |
| nanogram per milliliter (ng/mL) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| LCI699 Plasma Concentration Post LCI699 Administration at Day 7 | 1.51 ± 36 | 2.88 ± 41 | 3.92 ± 31 | 6.73 ± 23 |
| ng/mL | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of LCI699 | 1.42 ± 36 | 2.94 ± 35 | 4.62 ± 35 | 8.86 ± 21 |
| hour (hr) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| Time of Maximum Plasma Concentration (Tmax) of LCI699 | 2.21 (1.0 to 4.0) | 1.00 (1.0 to 4.0) | 1.00 (0.5 to 4.0) | 1.00 (1.0 to 3.0) |
| nanogram*hour per milliliter (ng*hr/mL) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8) | 6.60 ± 42 | 14.1 ± 30 | 24.1 ± 39 | 46.4 ± 13 |
| ng*hr/mL | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699 | 9.23 ± 50 | 18.8 ± 51 | 30.6 ± 41 | 68.9 ± 19 |
| hr | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD |
|---|---|---|---|---|
| Apparent Terminal Half-life (T1/2) of LCI699 | 4.67 ± 37 | 3.79 ± 43 | 5.52 ± 33 | 4.90 ± 17 |
An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.
| Participants | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Adverse Event (AEs) | 6 | 9 | 10 | 10 | 10 |
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.
| percentage of participants | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo |
|---|---|---|---|---|---|
| MSSBP Response | 58.3 | 50.0 | 69.2 | 76.9 | 61.5 |
| MSSBP Control | 50.0 | 41.7 | 61.5 | 76.9 | 53.8 |
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.
| percentage of participants | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo |
|---|---|---|---|---|---|
| MSDBP Response | 58.3 | 66.7 | 100 | 76.9 | 61.5 |
| MSDBP Control | 58.3 | 66.7 | 76.9 | 76.9 | 46.2 |
Collected over Up to 8 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: LCI699 0.5 mg QD | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Cohort A: LCI699 1.0 mg QD | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Cohort B1: LCI699 1.0 mg BID | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Cohort B1: LCI699 2.0 mg QD | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Placebo | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1.0 mg QD | Cohort B1: LCI699 1.0 mg BID | Cohort B1: LCI699 2.0 mg QD | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/12 | 4/12 | 2/13 | 2/13 | 3/13 |
| ACTH stimulation test abnormalInvestigations | 0/12 | 1/12 | 2/13 | 4/13 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/12 | 2/13 | 0/13 | 3/13 |
| DizzinessNervous system disorders | 2/12 | 0/12 | 3/13 | 0/13 | 1/13 |
| VomitingGastrointestinal disorders | 0/12 | 2/12 | 0/13 | 0/13 | 1/13 |
| SinusitisInfections and infestations | 0/12 | 0/12 | 1/13 | 2/13 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 1/12 | 0/12 | 0/13 | 0/13 | 0/13 |
| PalpitationsCardiac disorders | 0/12 | 1/12 | 0/13 | 0/13 | 0/13 |
| Abdominal painGastrointestinal disorders | 0/12 | 1/12 | 0/13 | 0/13 | 0/13 |
| Dry mouthGastrointestinal disorders | 1/12 | 0/12 | 0/13 | 0/13 | 0/13 |
Full analysis set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 56.1 ± 6.37 | 54.2 ± 16.01 | 57.9 ± 9.09 | 56.2 ± 10.37 | 56.8 ± 10.08 | 56.3 ± 10.52 |
| Sex: Female, Male(Participants) | Cohort A: LCI699 0.5 mg QD | Cohort A: LCI699 1 mg QD | Cohort B1: LCI699 1 mg BID | Cohort B1: LCI699 2 mg QD | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 5 | 3 | 5 | 4 | 21 |
| Male | 8 | 7 | 10 | 8 | 9 | 42 |
Ran from Jan 2009 to primary completion in Aug 2009, 6 months.
Results were first posted in Jun 2021, 11 years 9 months after primary completion. A results delay was requested in Nov 2012.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 6 months is below that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat